1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
IAM
Sector
Health Care
Subsector
Biotechnology
Offer Range
—
Shares Offered
—
—
Implied Upside vs Midpoint
Description
We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence. The Iambic molecular superintelligence platform is designed to disrupt legacy drug discovery paradigms. Instead of treating each stage of drug discovery as a distinct technological challenge, we have developed a unified, intelligent platform designed to address the full journey of drug discovery and development—from hit identification to multiparameter lead optimization to clinical developability. Our proprietary technologies include Enchant, a multimodal AI model for predicting preclinical and clinical properties, NeuralPLexer, a flow-matching generative AI for biomolecular structure prediction, and automated plate-based chemistry and biology workflows that allow synthesis and testing of hundreds of compounds per program on a weekly cadence. Crucially, the molecular superintelligence platform learns from its own laboratory-generated data: reinforcement learning based on a continuous stream of experiments sharpens predictions and search strategy, tightening the design–make–test (DMT) loop with every cycle. Although our approach is novel and unproven, in that it has not yet led to an approved drug product to date, we designed our molecular superintelligence platform to navigate chemical and biological spaces with the goal of improving the probability of success at every stage. There is no guarantee that our platform will lead to the successful completion of clinical trials or the approval of our product candidates, or the product candidates of partners and collaborators using our platform. However, Iambic aims to systematically expand the boundaries of what is druggable, and to redefine how novel therapeutics are conceived, optimized, and advanced to address unmet patient need. --- We believe that the utility of our platform is demonstrated through the advancement of our wholly owned pipeline of preclinical and clinical development candidates. We believe these programs each address indications with potential annual multi-billion dollar market opportunities, based on our estimates derived from reported sales of existing approved therapies for these indications. Our most advanced program, IAM1363, is an oral, highly selective, pan-mutant, and brain-penetrant small molecule inhibitor of human epidermal growth factor receptor 2 (HER2). As of September 2026, it is in an ongoing, open-label, multi-center Phase 1/1b basket clinical trial in patients with advanced HER2-altered solid tumors, and we anticipate initiating a registrational trial as early as 2027, subject to regulatory feedback. We believe IAM1363 is the only known HER2 tyrosine kinase inhibitor (TKI) that binds to the inactive (DFG-out) conformation of the HER2 kinase domain. We believe this distinct Type II binding mode may contribute to the molecule's combination of selectivity for HER2 vs wild-type epidermal growth factor receptor (EGFR), and broad coverage against HER2 variants with activating mutations. We believe IAM1363 has the potential to be developed across multiple HER2-driven solid tumor indications, including HER2-positive breast cancer, HER2-positive gastroesophageal adenocarcinoma (GEA), HER2-amplified non-small cell lung cancer (NSCLC), and HER2-mutant NSCLC. Evidence supporting the utility of our molecular superintelligence platform extends well beyond IAM1363, including a broad internal pipeline, continued innovation in new programs, and a growing roster of partnerships. Our molecular superintelligence platform drives a diverse set of internal programs, adding new modalities, target classes and therapeutic areas to our pipeline. IAM217 is a brain-penetrant allosteric inhibitor for KIF18A, a mitotic kinesin with potential therapeutic relevance for ovarian cancer, triple-negative breast cancer, and other solid-tumor cancers. IAM-C1 is our selective dual inhibitor of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4). We anticipate submitting Investigational New Drug (IND) applications for IAM217 and IAM-C1 in the fourth quarter of 2026, followed in each case by initiation of a Phase 1/2 clinical trial, subject to regulatory clearance. Target / Project How Iambic's Platform Technologies Were Used • Covalent pan-mutant inhibitor, discovery driven by ML HER2 pan-mutant coupled with microscale HTE inhibitor • Compound discovered without experimental structures for most mutants CDK2/4 dual • Structural hypothesis around selectivity inhibitor • Enchant directly predicted CDK4/6 and CDK4/7 selectivity and in vivo clearance • NeuralPLexer was fine-tuned and provided all structural enablement KIF18A allosteric • Candidate compound discovered without a high-resolution inhibitor experimental structure • Brain penetrance incorporated through AI-driven optimization • NeuralPLexer learned from minimal structural data to make RevMed predictions for unseen complexes collaboration • Work is supporting NeuralPLexer in glue-design projects --- Beyond our internal programs, the platform has been deployed across multiple strategic partnerships, extending these advantages to programs developed in collaboration with leading pharmaceutical companies. Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer reflect meaningful external interest in our platform, and are expanding the impact of our platform to additional target classes (for example, G protein-coupled receptors), additional therapeutic indications (for example, neurology, gastrointestinal, inflammation and immunology), and additional small-molecule mechanisms of action (for example, molecular glues, and glue degraders). Our goal is to prove, program after program, that better technology leads to better medicines—and that a platform built around molecular superintelligence has the potential to systematically improve the historical cost, time, and probability of success that have constrained drug development. Our vision is to deliver highly differentiated medicines to patients with urgent unmet needs, faster and with what we believe is a higher likelihood of success in clinical development than conventional approaches, while compounding a self-reinforcing advantage in data, technology, and pipeline of drug candidates. --- We were incorporated in Delaware in October 2019 under the name Entos, Inc. and subsequently changed our name to Iambic Therapeutics, Inc. Our principal executive offices are located at 5627 Oberlin Drive, Suite 120, San Diego, California 92121. Our telephone number is (619) 330-5499. Our website is www.iambic.ai.